Small group health insurance in California doesn’t have to be complicated. Learn how simple, flexible benefit strategies can help employers control costs, meet requirements, and give employees better options.

Hospital indemnity insurance is becoming a popular employee benefit as out-of-pocket healthcare costs continue to rise. Here’s what it is and why more employers are adding it to their benefits package.

Offering pre-tax benefits to your employees is a great way to save money and lower your payroll taxes. But did you know that this tax advantage is only allowed if you have the proper documentation in place?

For Applicable Large Employers (ALEs), ACA reporting is required annually to ensure compliance and avoid costly penalties. Here’s what you need to know for the 2024 tax season.

Discover why self-insured health plans gained traction among large employers in 2023.

Proposition 29, the third statewide dialysis initiative in the past 5 years in California, imposes new requirements on dialysis clinics such as requiring a doctor to be on hand during treatments. The other requirements included in the proposition would require clinics to report infections to the state and disclose when doctors have a stake in the clinic to patients.

The Medicare Modernization Act (MMA) requires employers to complete two disclosure requirements pertaining to the creditable coverage of their prescription drug plan.

The Newsom administration states that roughly 4 million Californians suffer from diabetes. One in 4 people with diabetes who rely on insulin cannot afford it, forcing many to ration the treatment or completely forego it, which can have deadly consequences.

Pfizer has reaped influence and outsized profits during the first two years of the pandemic. Their success in developing COVID medicines (both vaccines and treatment drugs) has given the drugmaker an unusual and unhealthy amount of weight and influence in developing and shaping U S health policy. Pfizer had a total revenue of 81.3 billion in 2021, nearly doubling their previous annual revenue in 2020. Pfizer’s MRNA COVID vaccine holds a 70% market share over U.S and European markets.